BioMarin Pharma (BMRN) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 set for muted open after big bank earnings, chip slide weighs
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.17 -0.4%
EPS Growth %: +1,008.3%
Financial Fact:
Total operating expenses: 339.98M
Today's EPS Names:
PGR, OMID, ACI, More
EPS Growth %: +1,008.3%
Financial Fact:
Total operating expenses: 339.98M
Today's EPS Names:
PGR, OMID, ACI, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 GAAP EPS of ($0.07), $0.05 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $334.1 million versus the consensus estimate of $349.59 million.
GUIDANCE:
BioMarin Pharma sees FY2017 revenue of $1.29-1.32 billion, versus the consensus of $1.31 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy
- Albertsons (ACI) Tops Q2 EPS by 3c
- UnitedHealth Group (UNH) Tops Q3 EPS by 57c, Beats on Revenue; Offers FY EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
